A topical sphingosine-1-phosphate receptor agonist active drug formulation is provided. A transdermal formulation embodiment includes an amount of a sphingosine-1-phosphate receptor agonist active in combination with a topical delivery vehicle, such as a topical patch comprising an adhesive layer and a backing layer. For example, to treat subjects with immune system diseases such as multiple sclerosis, hyperproliferative skin diseases such as psoriasis, acne, etc., a sphingosine-1-phosphate receptor agonist active agent A method of local delivery of a therapeutically effective amount is also provided. Packaged topical formulations, kits containing such formulations, and methods for producing such formulations are also provided. [Selection] Figure 1局所用スフィンゴシン－１－リン酸受容体アゴニスト活性薬製剤を提供する。経皮製剤の態様は、局所送達媒体、例えば、粘着層及びバッキング層を含む局所用パッチ剤との併用で、スフィンゴシン－１－リン酸受容体アゴニスト活性薬のある量を含む。例えば、多発性硬化症などの免疫系疾患、増殖過剰皮膚疾患、例えば、乾癬、ざ瘡、他などの病態の対象を治療するため、対象へのスフィンゴシン－１－リン酸受容体アゴニスト活性薬の治療効果量の局所送達方法も提供する。パッケージ化された局所用製剤、かかる製剤を含むキット、及びかかる製剤の製造方法も提供する。【選択図】図１
